Dianthus Therapeutics, Inc.
Dianthus Therapeutics (DNTH) is a clinical-stage biotechnology company advancing next-generation complement pathway inhibitors and bifunctional antibodies for severe autoimmune diseases, with recent positive Phase 2 data driving significant stock gains amid high clinical and financial risks typical of pre-revenue biotechs.
Fact:
Dianthus Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing potentially best-in-class therapies for patients with severe autoimmune and inflammatory diseases, primarily targeting the classical complement pathway and other immune mechanisms.
Key Pipeline
Fact: Founded in 2019 and headquartered in New York, NY. The company has approximately 92 full-time employees.
Interpretation: The company emerged from stealth with a focus on differentiated complement inhibition, leveraging experienced biotech leadership and backing from top-tier investors including 5AM Ventures, Fidelity, and Venrock.
Uncertainty: Exact founding details vary slightly across sources (some cite 2015); public listing occurred via SPAC/IPO transition around late 2023.
| Revenue (TTM) | $1.34M |
| Net Income (TTM) | -$173.66M |
| EPS (TTM) | -$4.23 |
| Cash & Equivalents (mrq) | $1.11B |
| Total Debt/Equity | 0.11% |
| Market Cap | ~$5.7B |
Fact: Pre-revenue clinical-stage company with strong cash runway.
Interpretation: Large cash position supports multiple Phase 2/3 trials.
Phase 2 MaGic trial in gMG completed enrollment; positive topline results presented at AAN/MDA conferences.
Company press releases →"GO" decision for Phase 3 CAPTIVATE trial in CIDP; Phase 3 in gMG planned for mid-2026.
Phase 2 MoMeNtum trial in MMN on track for topline Q4 2026.
| Firm | Rating | Target | Date |
|---|---|---|---|
| Wedbush | Outperform | $105 | May 6, 2026 |
| Guggenheim | Buy | $200 | Mar 2026 |
| Raymond James | Strong Buy | — | Jun 2026 |
| TD Cowen / Wolfe Research | Buy | — | 2026 |
Interpretation: As a clinical-stage company with no approved products, Dianthus has no current commercial customers or revenue-generating patients.
Potential Future Customers:
| Company / Product | Mechanism / Focus |
|---|---|
| Alexion (AstraZeneca) Soliris / Ultomiris |
C5 inhibitors (approved in gMG, PNH, etc.) |
| argenx Vyvgart |
FcRn blocker (gMG, CIDP) |
| UCB Rystiggo / Zilbrysq |
FcRn / C5 (gMG) |
| Sanofi Sutimlimab / Riliprubart |
C1s inhibitor (CAD; CIDP trials) |
| Apellis | C3 inhibitor (various indications) |